Exagen provides AVISE RADR presentation; no material operational or financial news

EXAGEN INC.

Exagen released updated investor presentation highlighting its AVISE RADR test for rheumatoid arthritis drug response.
Presentation dated January 10, 2022, focuses on the test's ability to predict drug response in RA patients.
Company did not disclose any new financial results, guidance, or material events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.